Immuneering Corp Class A

Research Immuneering Corp Class A (IMRX) on Bullrun: market cap USD 326.72M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIMRX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 326.72M
• Financial periodFY2025
• Net income-USD 56.02M
• Free cash flow-USD 45.49M

Valuation Snapshot

latest market cap is USD 326.72M.

About Immuneering Corp Class A

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors;

Frequently asked questions

What is Immuneering Corp Class A's market cap?

Immuneering Corp Class A's market capitalization is USD 326.72M.

What does Immuneering Corp Class A do?

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.